ROTH Capital resumed coverage on MindMed with a new price target
$MNMD
Medicinal Chemicals and Botanical Products
Health Care
ROTH Capital resumed coverage of MindMed with a rating of Buy and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $20.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $20.00 | Outperform | Leerink Partners |
| 7/24/2024 | $36.00 | Buy | ROTH MKM |
| 5/29/2024 | $27.00 | Outperform | Robert W. Baird |
| 4/15/2024 | $20.00 | Outperform | Leerink Partners |
| 12/5/2023 | $9.00 | Buy | Canaccord Genuity |
| 12/9/2022 | $25.00 | Buy | ROTH Capital |
| 11/16/2022 | $5.00 | Outperform | RBC Capital Mkts |
SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. "2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet (ODT) and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for maj
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Study builds on positive Phase 2b study results presented at the American Psychiatric Association's Annual Meeting in May 2024 - - Topline data from the 12-week double-blind period anticipated in the first half of 2026 - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are as follows: Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder Format: Poster Presenter: Paula Jacobson, Ph.D., Executive Director, Cli
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024-- --Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025-- --New patent issued by the United States Patent and Trademark Office (USPTO) extends intellectual property protection for MM120 ODT through 2041-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a
Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00
Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00
ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next